Share on LinkedInShare on LinkedIn

ARTICLE · 22 DECEMBER 2023

Market Intelligence Thought Leadership Award Winner

Supreme Court Refuses Teva Leave To Appeal Preliminary Injunction Order

William Fry LLP
William Fry LLP
Contributor
William Fry LLP

William Fry LLP

William Fry advises leading Irish and international companies, covering both the public and private...

View firm profile
Explore more from William Fry LLP

The injunction, which restrains Teva from launching a generic version of BMS' product Eliquis®, while BMS maintains a supplementary protection certificate (SPC) for its active ingredient...

IrelandLitigation, Mediation & Arbitration

The Supreme Court (Court) has refused Teva's application for leave to appeal a preliminary injunction granted to Bristol-Myers Squibb (BMS).

The injunction, which restrains Teva from launching a generic version of BMS' product Eliquis®, while BMS maintains a supplementary protection certificate (SPC) for its active ingredient, was granted by the High Court in February 2023 and upheld by the Court of Appeal (COA) in June 2023 (see our previous article on these decisions here.)

Applicant's submissions

In seeking leave to appeal the decision of the COA, Teva submitted that the COA:

  1. failed to apply the decision in Merck Sharp & Dohme v Clonmel Healthcare [2019] IESC 65 (Merck Sharp & Dohme) (see our article on the decision here), and instead applied a rigid approach that the presumed validity of the "impugned patent/SPC" displaced any countervailing interest or factor;

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from